This is the protocol for a review and there is no abstract. The objectives are as follows:
To evaluate the effects of interventions directed at preventing the progression of ADPKD on kidney function, such as GFR, serum creatinine (SCr), doubling of SCr concentration, ESKD, need for RRT, proteinuria or urinary albumin excretion.
To evaluate the effects of those interventions on total kidney volume, parenchymal volume, and kidney cyst volume.
To evaluate the effects of those interventions on patient-centred endpoints such as incidence of (fatal and non-fatal) cardiovascular events, sudden death, all-cause mortality, hospitalisations, blood pressure (BP) control, quality of life, and kidney pain.
To evaluate general and specific adverse effects related to those interventions such as dizziness, diarrhoea, abdominal cramps and nausea (all treatments); hypernatraemia, thirst, dry mouth, and headache (V2R-antagonists); angioedema and infections (mTOR inhibitors); alopecia (somatostatin agonists); and hyperkalaemia (ACEi and ARBs).